Taffic (Tenofovir Alafenamide + Emtricitabine + Bictegravir)

Tenofovir Alafenamide + Emtricitabine + Bictegravir
Contact us for more information
Цвет:
Вариант:
Wishlist Compare
Hetero Drugs Ltd

Taffic (Tenofovir Alafenamide + Emtricitabine + Bictegravir)

ManufacturerHetero Drugs LtdBrand nameTafficActive substanceTenofovir Alafenamide + Emtricitabine + BictegravirStrength25mg + 200mg + 50mgCategoryHIVManufacturerHetero Healthcare Ltd

Description of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) is an anti-retroviral drug containing three prominent factors is known as; Tenofovir Alafenamide Emtricitabine Bictegravir Tenofovir Alafenamide is a nucleotide transcriptase inhibitor Emtricitabine is a nucleoside reverse transcriptase inhibitor Bictegravir is an integrase inhibitor.
These are the most effective & a potent compound against HIV-1 infections, but it does not cure the infection situation it is only used for preventing & suppressing the evolution of HIV-1 infection into AIDS. In Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) tablets, TAF is present as a prodrug. Emtricitabine is synthetics fluoro derivative of thiacytodone. Bictegravir is an investigational drug. 

Medical use /Indication of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) is a combination tablet contains Tenofovir Alafenamide, Emtricitabine & Bictegravir is mainly indicated for the treatment of HIV-1 infection in adult’s patients.

Mechanism of Action Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) is a nucleoside reverse transcriptase inhibitor (carboxylic synthetic nucleoside analog), it has activity against human immunodeficiency virus type I.
Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) is phosphorylated into an active metabolite carbovir triphosphate (deoxyguanosine 5’triphosphate) dGTP.This active metabolite forbid the action of reverse transcriptase by spar with dGTP and inserted into viral DNA.
The growth of viral DNA gets concerned by the infusion of nucleotide which causes lack of OH molecule. OH, molecules are vital for the formation of 5’ to 3’ phosphodiester linkage which is guilty of chain extension.

Side effects of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

Common side effects:
• Depression
• Abnormal dreams
• Headache
• Dizziness
• Diarrhea
• Feeling sick (nausea)
• Tiredness (fatigue)
Uncommon side effects:
• Anemia
• vomiting
• Stomach pain
• Difficulty with digestion resulting in discomfort after meals (dyspepsia)
• wind (flatulence)
• swelling of the face, lips, tongue or throat (angioedema)
• itching (pruritus)
• Careless
• Joint pain (arthralgia)
• Suicidal behavior
• Tension
• sleep disorders

Precaution of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

The annoyance of HIV-1 infection: Patients should be considered earlier for the development of HIV infection or not. The influence of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) tablets for growing HIV-1 infection has not been assessing. These circumstances mostly occurred in patients who are HIV-1 co-infected.
Immune reconstitution syndrome: To overcome the problem by interrupting the treatment with Taffic. Renal deterioration worsening: Stop using Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) with drugs affecting the renal functions. Monitor the creatinine clearance value frequently. In severe conditions, CrCl below 30ml/min use of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should be avoided. Lactic acidosis & hepatic steatosis: Terminate the therapy using Taffic.

Drug interaction of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)+ P-GP or BCRP potent inhibitors: affect the consumption of TAF. Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)+ potent P-GP or BCRP inducers: decrease the consumption of TAF causes reducing=g the plasma concentration of TAF and certainly results as loss of effectiveness of Taffic. Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) removal process occurs through kidneys; a combination of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) with drugs affecting the renal activity causes increasing the effect of concentration of ingredients of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) & concludes as achieve of adverse effects associated with these components.
TafficTaffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) combines with drugs like Tipranavir/Ritonavir causes diminishing the effect of the concentration of TAF. Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) concurrently used with anti-convulsions causes decreasing the effect of concentration of TAF. Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) concurrently used with anti-mycobacterium or st Johns wort causes decreasing the effect of concentration of TAF. Inhibition of both CYP3A4 and UGT1A1 by a co-administered drug could potentially lead to significant increases in BIC exposure, while potent induction of these enzymes may significantly reduce BIC exposure.

Contraindication of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

Taffic  (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) has differed to patients with CrCl below 30ml/min Anaphylactic reactions are formed due to patients are contraindicated to the factor of Taffic.

Over dosage of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

The overdosage of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should be considered with hemodialysis. Emtricitabine should be evacuated by a 30% range after completing 3 hours of dialysis method. TAF should be removed by 54% of range after 4 hours dialysis session. Bictegravir is highly obligated to plasma proteins; it is strange that it will be necessarily removed by hemodialysis or peritoneal dialysis.

Pregnancy & Lactation of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

The usage of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) during pregnancy period is only occured by knowing the risk advantage combine to Taffic.

Pediatric of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

The efficiency & influence of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should not be calculated in pediatric patients with weighing below 25kg.

Geriatric of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

The efficiency of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should not be estimated in clinical trials for geriatric patients at the age of above 65 years.

Renal Damage of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

The uses of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should be prevented in patients with CrCl below 30ml/min.

Dosage of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

The prescribed dose of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) is one tablet that should be given orally as day-to-day. Important points; before starting the treatment, the patient should be considered for the presence of hepatitis B infection or not.
The patient’s renal values should be investigated for the creatinine approval, urine glucose & urine protein. Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should be used in adolescents, a pediatric patient with weighing at least 25kg & creatinine clearance of patients should be larger or equal to 30ml/min.
Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should not be suitable for patients with creatinine clearance below 30ml/min. Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) tablets should be executed with food or without food.

Storage of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

The storage of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should be kept at a temperature below 30℃ Preserve the container from humidity, heat & light.

Missed dose of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg)

If missed dose occurs, patient should be following the instructions provided by medical adviser. Missed dose of Taffic (Tenofovir Alafenamide 25mg + Emtricitabine 200mg + Bictegravir 50mg) should be avoided.Regular dosing schedule should be maintained.

 

Brand name:
Taffic
Active substance:
Tenofovir Alafenamide + Emtricitabine + Bictegravir
Strength:
25mg + 200mg + 50mg
Category:
HIV
Manufacturer:
Hetero Healthcare Ltd
Packaging:
30 Tablet
Product form:
Tablet

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India